Y-Mabs Therapeutics Inc [YMAB] stock prices are up 10.12% to $15.13 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The YMAB shares have gain 21.14% over the last week, with a monthly amount glided 20.75%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Y-Mabs Therapeutics Inc [NASDAQ: YMAB] stock has seen the most recent analyst activity on August 16, 2024, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $20. Previously, Truist started tracking the stock with Buy rating on June 28, 2024, and set its price target to $21. On May 10, 2023, upgrade upgraded it’s rating to Outperform and revised its price target to $13 on the stock. Guggenheim downgraded its rating to a Neutral. Morgan Stanley downgraded its rating to a Underweight but $4 remained the price target by the analyst firm on January 27, 2023. Cowen downgraded its rating to Market Perform for this stock on January 05, 2023. In a note dated December 02, 2022, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $23 to $5.
The stock price of Y-Mabs Therapeutics Inc [YMAB] has been fluctuating between $4.69 and $20.90 over the past year. Currently, Wall Street analysts expect the stock to reach $20.5 within the next 12 months. Y-Mabs Therapeutics Inc [NASDAQ: YMAB] shares were valued at $15.13 at the most recent close of the market. An investor can expect a potential return of 35.49% based on the average YMAB price forecast.
Analyzing the YMAB fundamentals
The Y-Mabs Therapeutics Inc [NASDAQ:YMAB] reported sales of 86.55M for trailing twelve months, representing a surge of 9.86%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -0.32%, Pretax Profit Margin comes in at -0.28%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.25 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.14 points at the first support level, and at 13.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.70, and for the 2nd resistance point, it is at 16.27.
Ratios To Look Out For
It’s worth pointing out that Y-Mabs Therapeutics Inc [NASDAQ:YMAB]’s Current Ratio is 2.92. As well, the Quick Ratio is 2.72, while the Cash Ratio is 1.79. Considering the valuation of this stock, the price to sales ratio is 7.79, the price to book ratio is 7.07.
Transactions by insiders
Recent insider trading involved Wilms Joris, Officer, that happened on Aug 26 ’24 when 5000.0 shares were purchased. Director, Ber Gerard completed a deal on Jun 10 ’24 to sell 722.0 shares. Meanwhile, CHIEF BUSINESS OFFICER Gad Thomas sold 35000.0 shares on Jun 10 ’24.
